Sullivan & Cromwell advised Merck KGaA, Darmstadt, Germany, while Goodwin Procter advised SpringWorks Therapeutics on the transaction. Skadden advised Centerview Partners and Goldman Sachs & Co....
Merck’s $3.9 Billion Acquisition of SpringWorks Therapeutics
Jade Biosciences’ Merger with Aerovate Therapeutics
Gibson, Dunn & Crutcher advised Jade Biosciences on the transaction, and Cooley advised the placement agents; while Goodwin Procter advised Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc....
Merck’s $680 Million Acquisition of Harpoon Therapeutics
Evercore Group L.L.C. acted as financial advisor to Merck in this transaction and Covington & Burling LLP acted as its legal advisor. Centerview Partners LLC acted...
Novo Nordisk’s Research Collaborations with Omega Therapeutics and Cellarity
Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...
Novo Nordisk’s $1.3 Billion Acquisition of Ocedurenone
KBP Biosciences was represented by Goodwin Procter LLP and Novo Nordisk was represented by Covington & Burling LLP in this transaction. Novo Nordisk A/S and KBP...
Kyowa Kirin’s $387 Million Acquisition of Orchard Therapeutics
Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
Mercy BioAnalytics’ $41 Million Series A Financing
Goodwin advised Mercy BioAnalytics, Inc. on the deal. Mercy BioAnalytics, Inc. announced its $41 million Series A financing round. The financing was led by Novalis LifeSciences, with...
Sun Pharmaceutical’s $576 Million Acquisition of Concert Pharmaceuticals
Davis Polk advised Sun Pharmaceutical, and Goodwin Procter advised Concert Pharmaceuticals. Sun Pharmaceutical Industries Limited announced its acquisition of Concert Pharmaceuticals Inc., through a tender offer for an...
Takeda’s Acquisition of NDI-034858 from Nimbus Therapeutics
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
Nimbus Therapeutics’ Research Collaboration and License Agreement with Eli Lilly and Co.
Goodwin Procter advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced its Research Collaboration and License Agreement with Eli Lilly and Company for the exclusive and worldwide...
SpringWorks Therapeutics’ $300 Million Shares Private Placement
Goodwin Procter advised SpringWorks Therapeutics on the deal. SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced its private placement transaction with a select group of institutional investors to issue...
Novo Nordisk’s $1.1 Billion Acquisition of Forma Therapeutics
Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...